Tobacco Money Pot: Half Full or Half Empty?

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

WASHINGTON-More than beauty lies in the eye of the beholder. For example, the National Conference of State Legislatures (NCSL) and the Campaign for Tobacco Free Kids offered quite different interpretations of a report released by NCSL at its annual meeting.

WASHINGTON—More than beauty lies in the eye of the beholder. For example, the National Conference of State Legislatures (NCSL) and the Campaign for Tobacco Free Kids offered quite different interpretations of a report released by NCSL at its annual meeting.

The report examined the allocation by the states of monies received from the tobacco industry as the result of successful lawsuits or the settlement agreement that ended the lawsuits of 46 states and the District of Columbia. During fiscal years 2000 to 2002, the report said, 49 states allocated $21.283 billion.

Noting that nearly 46% of the money received in the last several years has gone to various forms of health care, the NCSL chose to emphasize that the largest single beneficiary of the tobacco settlement funds has been health care. More than $1 billion was spent on tobacco cessation and prevention between 1999 and 2001.

"Under the agreement, states have been given a great deal of flexibility in how they use their revenue," said Lee Dixon, director, NCSL Health Policy Tracking Service. "Right now, it is clear that states are committed to improving the quality and access of the health care programs that they offer."

However, the Campaign for Tobacco Free Kids focused on the fact that only 5% of the total funds received have been allocated to tobacco programs. "The large majority of states are breaking their promise to use proceeds to fund effective tobacco prevention programs," said Campaign president Matthew L. Myers.

Forty of the 49 states have funded tobacco prevention efforts and health services from the industry payments; 20 have allocated tobacco monies for endowments and budget reserves. Six states have used part of the money to institute programs to aid tobacco farmers and the communities that depend on tobacco growing for their economic strength. 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video